207 related articles for article (PubMed ID: 12383116)
1. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.
Zheleva DI; McInnes C; Gavine AL; Zhelev NZ; Fischer PM; Lane DP
J Pept Res; 2002 Nov; 60(5):257-70. PubMed ID: 12383116
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
3. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
Flink IL; Oana S; Maitra N; Bahl JJ; Morkin E
J Mol Cell Cardiol; 1998 Mar; 30(3):563-78. PubMed ID: 9515032
[TBL] [Abstract][Full Text] [Related]
4. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes.
Adams PD; Li X; Sellers WR; Baker KB; Leng X; Harper JW; Taya Y; Kaelin WG
Mol Cell Biol; 1999 Feb; 19(2):1068-80. PubMed ID: 9891042
[TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
6. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
7. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1.
Ball KL; Lain S; Fâhraeus R; Smythe C; Lane DP
Curr Biol; 1997 Jan; 7(1):71-80. PubMed ID: 8999999
[TBL] [Abstract][Full Text] [Related]
8. Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein.
Nakanishi M; Kaneko Y; Matsushime H; Ikeda K
Biochem Biophys Res Commun; 1999 Sep; 263(1):35-40. PubMed ID: 10486249
[TBL] [Abstract][Full Text] [Related]
9. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors.
Adams PD; Sellers WR; Sharma SK; Wu AD; Nalin CM; Kaelin WG
Mol Cell Biol; 1996 Dec; 16(12):6623-33. PubMed ID: 8943316
[TBL] [Abstract][Full Text] [Related]
10. Characterization of murine gammaherpesvirus 68 v-cyclin interactions with cellular cdks.
Upton JW; van Dyk LF; Speck SH
Virology; 2005 Oct; 341(2):271-83. PubMed ID: 16102793
[TBL] [Abstract][Full Text] [Related]
11. Doenjang hexane fraction-induced G1 arrest is associated with the inhibition of pRB phosphorylation and induction of Cdk inhibitor p21 in human breast carcinoma MCF-7 cells.
Choi YH; Choi BT; Lee WH; Rhee SH; Park KY
Oncol Rep; 2001; 8(5):1091-6. PubMed ID: 11496322
[TBL] [Abstract][Full Text] [Related]
12. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.
McInnes C; Andrews MJ; Zheleva DI; Lane DP; Fischer PM
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):57-69. PubMed ID: 12678915
[TBL] [Abstract][Full Text] [Related]
13. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A.
Lowe ED; Tews I; Cheng KY; Brown NR; Gul S; Noble ME; Gamblin SJ; Johnson LN
Biochemistry; 2002 Dec; 41(52):15625-34. PubMed ID: 12501191
[TBL] [Abstract][Full Text] [Related]
14. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
Chen WJ; Chang CY; Lin JK
Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
[TBL] [Abstract][Full Text] [Related]
15. New structural insights into phosphorylation-free mechanism for full cyclin-dependent kinase (CDK)-cyclin activity and substrate recognition.
Zheng F; Quiocho FA
J Biol Chem; 2013 Oct; 288(42):30682-30692. PubMed ID: 24022486
[TBL] [Abstract][Full Text] [Related]
16. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
[TBL] [Abstract][Full Text] [Related]
17. p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.
Zhu L; Harlow E; Dynlacht BD
Genes Dev; 1995 Jul; 9(14):1740-52. PubMed ID: 7622038
[TBL] [Abstract][Full Text] [Related]
18. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery.
Jensen SS; Madsen MW; Lukas J; Binderup L; Bartek J
Mol Endocrinol; 2001 Aug; 15(8):1370-80. PubMed ID: 11463860
[TBL] [Abstract][Full Text] [Related]
20. Control of E2F activity by p21Waf1/Cip1.
Delavaine L; La Thangue NB
Oncogene; 1999 Sep; 18(39):5381-92. PubMed ID: 10498892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
